1-3 of 3
creatine phosphokinase serum increased
Close
Sort by
Journal Articles

Comparative Risk Assessment of Imatinib, Nilotinib and Dasatinib in Randomized Controlled Trials: A Meta-Analysis

Ahmad Ghorab, MDMSc, Hagop M. Kantarjian, MD, Hesham Elhalawani, MD MS, Hoda Ahmed, MD MS, Ahmed Essam, MD, Omar Abdel-Rahman, MD PhD, Elias J. Jabbour, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2869.
https://doi.org/10.1182/blood.V130.Suppl_1.2869.2869
Published: 2017
Journal Articles

Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts

Jason Kaplan, MD, Leo I. Gordon, MD, Alessandro Rambaldi, MD Prof, Giuseppe Gritti, MD, Rakesh Popat, MD PhD, Howard A. Burris, MD, Manish R Patel, MD, Sumit Madan, MD, Ian Chau, MD, John A. Radford, MD, Swami P. Iyer, MD, Jaime Perez De Oteyza, MD, Pier Luigi Zinzani, MD, Shining Wang, MD, Emily Sheldon-Waniga, PhD, Kate Stumpo, BA, Yaping Shou, MD PhD, Cecilia Carpio, MD, Francesc Bosch, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1554.
https://doi.org/10.1182/blood.V130.Suppl_1.1554.1554
Published: 2017
Journal Articles

HyperCKemia in CML Patients on Imatinib Mesylate.

Joanne D. Hewitt, BScN, Deborah A. Rusnak, RN, Nanette Cox-Kennett, MN, Loree M. Larratt, MD, Robert Turner, MD
Journal: Blood
Blood (2007) 110 (11): 2965.
https://doi.org/10.1182/blood.V110.11.2965.2965
Published: 2007